Molecular basis of inhibition of substrate hydrolysis by a ligand bound to the peripheral site of acetylcholinesterase.
Acetylcholinesterase (AChE) contains a narrow and deep active site gorge with two sites of ligand binding, an acylation site (or A-site) at the base of the gorge and a peripheral site (or P-site) near the gorge entrance. The P-site contributes to the catalytic efficiency of substrate hydrolysis by transiently binding substrates on their way to the acylation site, where a short-lived acyl enzyme intermediate is produced. Ligands that bind to the A-site invariably inhibit the hydrolysis of all AChE substrates, but ligands that bind to the P-site inhibit the hydrolysis of some substrates but not others. To clarify the basis of this difference, we focus here on second-order rate constants for substrate hydrolysis (k(E)), a parameter that reflects the binding of ligands only to the free form of the enzyme and not to enzyme-substrate intermediates. We first describe an inhibitor competition assay that distinguishes whether a ligand is inhibiting AChE by binding to the A-site or the P-site. We then show that the P-site-specific ligand thioflavin T inhibits the hydrolysis of the rapidly hydrolyzed substrate acetylthiocholine but fails to show any inhibition of the slowly hydrolyzed substrates ATMA (3-(acetamido)-N,N,N-trimethylanilinium) and carbachol. We derive an expression for k(E) that accounts for these observations by recognizing that the rate-limiting steps for these substrates differ. The rate-limiting step for the slow substrates is the general base-catalyzed acylation reaction k(2), a step that is unaffected by bound thioflavin T. In contrast, the rate-limiting step for acetylthiocholine is either substrate association or substrate migration to the A-site, and these steps are blocked by bound thioflavin T.
Auletta
Jeffrey T
JT
Mayo Clinic College of Medicine, Department of Neuroscience and Pharmacology, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Johnson
Joseph L
JL
Rosenberry
Terrone L
TL
D000110:Acetylcholinesterase / Q000737:chemistry* / Q000378:metabolism*; D000122:Acetylthiocholine / Q000031:analogs & derivatives / Q000378:metabolism; D000818:Animals; D052160:Benzothiazoles; D001667:Binding, Competitive; D002217:Carbachol / Q000031:analogs & derivatives / Q000378:metabolism; D020134:Catalytic Domain; D002460:Cell Line; D002800:Cholinesterase Inhibitors / Q000378:metabolism* / Q000494:pharmacology*; D018360:Crystallography, X-Ray; D006801:Humans; D006868:Hydrolysis / Q000187:drug effects; D007700:Kinetics; D008024:Ligands; D000644:Quaternary Ammonium Compounds / Q000737:chemistry / Q000378:metabolism; D013379:Substrate Specificity; D013844:Thiazoles / Q000378:metabolism / Q000494:pharmacology
D052160:Benzothiazoles; D002800:Cholinesterase Inhibitors; D008024:Ligands; D000644:Quaternary Ammonium Compounds; D013844:Thiazoles; C009462:thioflavin T; C009571:phenyltrimethylammonium; D000122:Acetylthiocholine; D002217:Carbachol; D000110:Acetylcholinesterase